is associated with CCAAT enhancer-binding protein β upregulation. 2 3
Abstract
Obese adipose tissue (AT) exhibits increased macrophage number. Pro-inflammatory CD16 + 29 peripheral monocyte numbers are also reported to increase with obesity. The current study was 30 undertaken to simultaneously investigate obesity-associated changes in CD16 + monocytes and adipose 31 tissue macrophages (ATM). In addition, a pilot randomised placebo controlled trial using the 32 peroxisome proliferator-activated receptor (PPAR) agonists, pioglitazone and fenofibrate was 33 performed to determine their effects on CD14 + /CD16 + monocytes, ATM and cardiometabolic and 34 adipose dysfunction indices. Obese glucose-tolerant men (n=32) were randomised to placebo, 35 pioglitazone (30 mg/day) and fenofibrate (160 mg/day) for 12 weeks. A blood sample was taken to 36 assess levels of serum inflammatory markers and circulating CD14 + /CD16 + monocyte levels via flow 37 cytometry. A subcutaneous (sc) AT biopsy was performed to determine adipocyte cell surface and AT 38 macrophage (ATM) number, the latter was determined via assessment of CD68 expression by 39 immunohistochemisty (IHC) and real time PCR. SC AT mRNA expression of CCAAT enhancer-40
binding protein β (CEBPβ), sterol regulatory element-binding protein 1c (SREBP1c), PPARγ2, 41
insulin receptor substrate 1 (IRS-1), glucose transporter type 4 (GLUT 4) and tumour necrosis factor α 42
(TNF-α) were also assessed. Comparisons were made between obese and lean controls (n=16) at 43 baseline, and pre-and post-PPAR agonist treatment. Obese individuals had significantly increased 44 adipocyte cell surface, % CD14 + /CD16 + monocyte numbers and ATM number (all p=0.0001). 45 Additionally, serum TNF-α levels were significantly elevated (p=0.017) and adiponectin levels 46 reduced (total: p=0.0001; high: p=0.022) with obesity. ATM number and % of CD14 + /CD16 + 47 monocytes correlated significantly (P=0.05). Pioglitazone improved adiponectin levels significantly 48 (p=0.0001), and resulted in the further significant enlargement of adipocytes (p=0.05), without effect 49 on % CD14 + /CD16 + or ATM number. Pioglitazone treatment also significantly increased sc AT 50 expression of CEBPβ mRNA. The finding that improvements in obesity-associated insulin resistance 51
following pioglitazone were associated with increased adipocyte cell surface and systemic adiponectin 52 levels, supports the centrality of AT to the cardiometabolic derangement underlying the development 53 of T2D and CVD. 54
Methods 105
Study design 106 The protocol for the randomised placebo controlled trial was approved by Office for Research Ethics 107
Committees Northern Ireland (reference number 06/NIR03/146) and clinical trial details were logged 108 in the EudraCT database ( A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
5'-TGCAACACAGCAACCAGAAAC-3'; reverse 5'-TTGCTTTTGTGGACAGCAGTG-3'), glucose 211
transporter type 4 (GLUT 4) (GenBank accession no. NM_001042; forward 5'-212 ATGTTGCGGAGGCTATGGG-3'; reverse 5'-GGAGGACCGCAAATAGAAGGA-3'), insulin 213 receptor substrate 1 (IRS-1) (GenBank accession no. NM_005544; forward 5'-214 TGAGGATTTAAGCGCCTATGC-3'; reverse 5'-TTGAGCTACTGACGGTCCTCTG-3') and TNF-215 α (GenBank accession no. NM_000594; forward 5'-ATCTTCTCGAACCCCGAGTGA-3'; reverse R 216 5'-GGGTTTGCTACAACATGGGC-3'). PCR was performed in triplicate with cycle threshold (Ct) 217
values calculated automatically using the Sequence detection software version 1.2.3 (Applied 218
Biosystems). The house keeping genes used were glyceraldehyde 3-phosphate dehydrogenase 219
(GAPDH) (GenBank accession no. NM_002046; forward 5'-ATCCATGACAACTTTGGTATCGTG-220 3'; reverse 5'-GGCATGGACTGTGGTCATGAG-3'), ribosomal protein large P 0 (RPLP0) 221
(GenBank accession no. NM_001002; forward 5'-GGCGTCCTCGTGGAAGTGACAT-3'; reverse 222
5'-CAGGGATTGCCACGCAGGGT-3') and 18S (GenBank accession no. NR_003286; forward 5'-223 CGGAGGTTCGAAGACGATCA-3'; reverse 5'-GGCATCGTTTATGGTCGGAA-3'). These 224
housekeeping genes have been used in previous gene expression analyses in AT and, in agreement 225
with previous studies [19] [20] [21] , in the current study expression of none of the three housekeeping genes 226
were found to be altered by either obesity or treatment. Individual subject gene expression was 227 normalised to the relevant housekeeping gene [delta Ct (ΔCt)]. For comparison of lean vs obese gene 228 expression, the obese group mean fold change relative to the lean control group was calculated using 229 the group mean ΔCt values in the formula 2^-ΔΔCt . Differences between lean and obese ΔCt values 230
were analysed using independent t-tests and a p value less than or equal to 0.05 was considered 231 statistically significant. For pre-vs post-treatment comparisons, individual obese subject post-232 treatment mRNA expression was calculated as a fold change relative to pre-treatment for each 233 participant using the formula 2^-ΔΔCt . Differences between pre-and post-treatment ΔCt values were 234 analysed using paired t-tests. Treatment change (post -pre) was compared with placebo change (post 235 -pre) by independent t-test. A p value less than or equal to 0.05 was considered statistically 236 significant. 237 238
Statistical analysis 239
Statistical analyses were carried out using SPSS software version 18.0. Lean and obese groups were 240 compared at baseline by independent t-test; obese treated groups were analysed by calculating the 241 change (post -pre) and comparing with placebo change (post -pre) also using independent t-tests. 242
Correlations between continuous variables were assessed by Pearson's coefficients for correlations. 243
Logistic regression analysis was used to determine if existing correlations remained once BMI was 244 added to the model. 245
Individual subject ΔCt values were used to assess correlations between mRNA expression and 246 continuous variables and, as higher ΔCt values reflect lower mRNA expression, negative correlations 247
do not represent inverse relationships between variables. Variables not normally distributed were log 248 transformed to natural logarithms prior to analysis to allow for parametric testing. Serum results were 249 obtained from fasting variables and all results are presented as mean ± standard deviation (S.D). A p 250
value less than or equal to 0.05 was considered statistically significant. 
Results

252
Anthropometric and biochemical characteristics of study participants 253
Baseline anthropometric and biochemical characteristics of study participants are shown in Table 1 . 254
As expected, both BMI and WHR were significantly increased in the obese group relative to the lean 255 group. Additionally, the lean group displayed significantly lower systolic blood pressure (SBP) and 256 diastolic blood pressure (DBP) compared with baseline levels in the obese group. The obese group 257 displayed significantly greater glucose levels at baseline. Nonetheless, levels after 120 minutes of the 258
OGTT were not significantly different between groups, indicating that despite obesity, participants 259 who entered the study had normal glucose tolerance. In support of this, there was no significant 260 difference in HbA 1c levels between the groups. There were two surrogate markers of insulin resistance 261 used in the study: fasting insulin levels and HOMA index. Both parameters were significantly lower 262
in the lean participants compared to the obese, signifying insulin resistance within the obese group. 263
Severe dyslipidaemia was an exclusion criterion in the study; this would indicate why TC and LDL-C 264
were similar between the two groups. In keeping with dyslipidaemic features associated with obesity, 265
HDL-C was significantly higher and TGs lower in the lean individuals relative to the obese. 266
Additionally, both the TC/HDL-C ratio and LDL-C/HDL-C ratio were significantly increased with 267 obesity. 268 269
Cytokine and peripheral monocyte levels and adipocyte cell surface assessment 270
As expected, baseline levels of TNF-α were significantly higher in the obese participants compared to 271 the lean (Table 2) . Additionally, levels of total and high adiponectin were significantly reduced with 272
obesity (Table 2 ). There was no significant difference in the high to total adiponectin ratio between 273
the two groups. p<0.0001] was significantly elevated with obesity (Figure 2a ). In parallel, CD68 mRNA expression 282 followed a similar trend, with a 1.62 fold increase in the obese group relative to the lean group ( Figure  283 2b).
285
Adipose tissue gene expression analysis 286
The observed obesity-associated increases in circulating TNF-α levels were reflected in a significant 287 increase in sc adipose tissue expression of this cytokine (Figure 3 ). Expression of SREBP1c, CEBPβ, 288
GLUT 4 and IRS-1 were all lower in obese vs lean adipose tissue, however, only the latter was 289 significant (Figure 3 ). Expression of PPAR2 was similar between lean and obese adipose tissue. 290 291
Correlations between adipose markers, peripheral monocytes and CVD risk factors 292
In agreement with the observation that obesity-associated increases in % of CD68 cells within AT 293 (Figure 2a ), BMI and WHR demonstrated positive correlations with % of CD68 expressing cells in sc 294
AT (r=0.595, p=0.001, and r=0.429, p=0.023, respectively). 295
As can be seen in Figure 4a percentage of CD14 + /CD16 + monocytes also showed a positive correlation with fasting insulin 306 (r=0.378, p=0.048) and HOMA index (r=0.422, p=0.023), and a negative correlation with total 307 adiponectin (r= 0.428, p=0.007), as well as high adiponectin (r= 0.362, p=0.025). Likewise, the 308 percentage of CD68 expressing AT cells negatively correlated with total ( 0.578, p=0.001) and high 309 adiponectin (r= 0.460, p=0.012). Again, correlations between CD14 + /CD16 + monocytes and indices 310 of insulin resistance and circulating levels of adiponectin isoforms became non-significant when 311 adjusted for BMI, as did correlations between % of CD68 expressing AT cells and adiponectin. 312 313
The effects of pioglitazone and fenofibrate on anthropometric and biochemical characteristics 314
The effects of pioglitazone and fenofibrate on anthropometric and biochemical characteristics are 315
shown in Table 3 . Fasting insulin levels and HOMA index both improved significantly following 316 pioglitazone treatment, demonstrating its ability to ameliorate obesity associated insulin resistance. As 317 expected, fenofibrate exhibited its lipid-lowering effects by significantly reducing levels of TC, LDL-318 C and TG, and improving the TC/HDL-C ratio and the LDL-C/HDL-C ratio. In addition, pioglitazone 319 significantly enhanced HDL-C levels and had similar positive effects to fenofibrate on the TC/HDL-C 320 ratio and the LDL-C/HDL-C ratio. The
effects of pioglitazone and fenofibrate on adipose tissue gene expression 335
Fenofibrate was without effect on the expression levels of any of the genes examined. Pioglitazone 336 significantly increased expression of CEBPβ ( Figure 5 ; 4.26 fold). Pioglitazone treatment also 337 resulted in increased expression of SREBP1c, PPAR2, GLUT 4, and IRS-1, albeit that none of these 338 increases reached significance ( Figure 5 ). 339
Following pioglitazone treatment, CEBPβ expression exhibited significant positive correlations with 340
IRS-1(r=0.979, p<0.0001) and SREBP1c (r=0.976, p<0.0001) mRNA levels, and a significant 341 negative correlation with CD68(r= 0.822, p=0.045) mRNA expression. 342
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Discussion
343
Using a cohort of lean and obese glucose tolerant subjects this study is the first to simultaneously 344 investigate obesity-associated changes in both peripheral blood CD14 + /CD16 + monocytes and ATM. 345
The results obtained indicate that obesity is associated with increased peripheral CD14 + /CD16 + 346 monocyte and sc ATM number, as well as increased sc adipocyte cell surface, reduced circulating 347 adiponectin levels and lower sc AT expression of genes involved in macrophage phenotype, 348 adipogenesis and glucose metabolism. Moreover, pioglitazone treatment was found to result in 349 significant improvements in insulin resistance and lipid profile, changes which occurred in parallel [5.6-6.9 mmol/L]) or an HbA 1c of 5.7-6.4% [22] . A strength of the current study is that the obese 359 subjects recruited did not have impaired glucose tolerance (2hr glucose 6.4±1.0 mmol/L; fasting 360 glucose concentration 5.3±0.4 mmol/L; HbA1c 5.3±0.3%), thereby, enabling obesity-associated 361 changes in primary and secondary endpoints to be investigated and the impact of PPAR agonist 362 treatment on these endpoints to be evaluated. Cardioprotective strategies, including lifestyle 363 modification, have been shown to be most effective in averting or delaying the onset of diabetes when 364 administered at this early stage in the hyperglycaemia/diabetes continuum [23] . The current study has 365
provided evidence that preventative strategies are also effective when administered prior to the 366 development of impaired glucose tolerance. 367
Subcutaneous and visceral ATM number increase in obesity and evidence is accumulating that ATM 368 are responsible for potentiating the chronic inflammatory processes of obesity [1, 2] . The origin of 369 ATM remains to be fully elucidated, it has been reported that these arise from adipokine-dependent 370 extravasated peripheral blood monocytes and evidence has also been presented that multi-potent 371 adipocyte stem cells and pre-adipocytes can differentiate into macrophages [24, 25] . Both sc and 372 visceral ATM number have been reported to correlate with clinical parameters of obesity and its co-373
morbidities [18] . The results of the current study concur with previous reports, the percentage of 374 CD68 expressing cells within AT was significantly elevated in obesity, while CD68 mRNA 375 expression followed a similar trend. Moreover, BMI and WHR demonstrated positive correlations 376
with the percentage of CD68 expressing cells in sc AT. The percentage of CD68 expressing cells also 377 negatively correlated with total and high adiponectin levels, indicating that ATM infiltration is 378 associated with reduced adipocyte function. Adipocyte enlargement is a strong, direct predictor of 379
ATM recruitment and accumulation [26] . Macrophages have been detected in the sc and visceral AT 380 of obese patients, in which they surround the dead adipocyte in a crown-like arrangement [27] . Given 381 the evidence that adipocyte hypertrophy is a potential stimulus for ATM infiltration, it is of interest 382
that, in the current study, adipocyte cell surface correlated significantly with both % of CD68 383 expressing cells in sc AT and % of peripheral CD14 + /CD16 + monocytes. Given the observed obesity-384 associated increases in the CD14 + /CD16 + peripheral monocyte population, the significant correlation 385 between % of CD68 expressing cells in sc AT and % of peripheral CD14 + /CD16 + monocytes, and the 386 evidence supporting a role for this population in vascular inflammation, it is tempting to speculate that 387 these represent a source of the increased ATM number in sc AT, however, clearly this is an area that 388 requires further analysis. 389
The observation in the current study that pioglitazone and fenofibrate normalised obesity-associated 390 insulin resistance and/or dyslipidaemia is as would be expected, indeed, in an earlier study similar 391 results were reported by our group [11] . The observation that pioglitazone achieved this without 392 significantly changing % of peripheral CD14 + /CD16 + monocytes or ATM number, but by 393 significantly increasing adipocyte cell surface and improving adipocyte function is a novel one. 394 Taken together, these results suggest a model whereby modulation of adipocyte function, in the 395 absence of effects on CD14 + /CD16 + monocyte expansion or ATM number, results in cardioprotective 396
outcomes. While Di Gregorio and co workers [28] have reported a decrease in ATM following 397 pioglitazone treatment, their cohort received a higher dose than used in the current trial (45 mg/day), 398 moreover, their subjects had impaired glucose tolerance and were mixed gender. Hammarstedt and 399 co-workers have reported that 3 week treatment with a similar dose of pioglitazone in overweight, 400
insulin resistant, glucose tolerant subjects had no effect on adipocyte cell surface, or indeed, in 401 agreement with the results of the current study, adipose macrophage infiltration markers [29] . In 402
contrast to the current study, however, short term pioglitazone treatment was found to be without 403 effect on lipid levels [29] . PPAR agonists are reported to promote free fatty acid uptake and storage 404 in adipocytes, thereby preventing lipotoxic trauma to liver and muscle and ameliorating insulin 405
resistance. In support of this, pioglitazone has been demonstrated to increase sc adipose mass [30] . 406
Moreover, it has been reported that congenital adrenal hyperplasia-associated insulin resistance was 407 improved by pioglitazone treatment, and that this improvement in insulin sensitivity was associated 408
with enlargement of sc adipocytes [12] . 409
A further novel finding of the current study is that, following pioglitazone treatment, sc AT CEBPβ 410
expression was significantly increased. Expression of CEBPβ, SREBP1c, GLUT 4 and IRS-1 were 411 all lower in obese vs lean sc AT, the latter being significantly reduced. These results are in keeping 412
with an obesity-associated impairment in adipogenesis [1] . CEBPβ has been recently identified as a 413
playing a central role in PPAR-mediated gene regulation in both adipocytes and macrophages, two 414 cell types which predominate in obese sc AT [31, 32] . In addition, evidence has been presented that 415
CEBPβ plays a non-PPAR-dependent role in mitotic clonal expansion during adipogenesis [33] . 416
The observation that pioglitazone upregulates CEBPβ is interesting given the central role of this 417 transcription factor in adipogenesis and macrophage polarisation, and provides evidence that 418
pioglitazone, in addition to increasing the function/size of mature adipocytes, promotes adipogenesis 419
and may facilitate macrophage polarisation to the alternative, anti-inflammatory phenotype. It will be 420 of interest in future studies to determine if pioglitazone-dependent CEBPβ upregulation is reflected in 421 increased protein levels of this transcription factor and whether this is associated with an increase in 422 anti-inflammatory, and a decrease in proinflammatory, cytokine expression, as demonstrated in our 423
previous study [11] . Pioglitazone treatment also resulted in increased, albeit non-significant, sc 424 adipose expression of SREBP1c, PPAR2, GLUT 4, and IRS-1. These results are in broad agreement 425
with the findings of Hammarstedt et al [29] , and further support a model whereby pioglitazone 426 treatment facilitates adipocyte terminal differentiation. 427
In conclusion, the current study has found evidence that increased adipocyte cell surface, expansion of 428 the CD14 + /CD16 + monocyte population and ATM number, and compromised AT function occurs in 429 obese individuals prior to the development of impaired glucose tolerance. Further, significant 430 associations between adipocyte cell surface and increased peripheral monocyte and ATM numbers 431 support the role of adipocyte enlargement as an initiating stimulus in adipose 432 inflammation/dysfunction. The finding that improvements in obesity-associated insulin resistance 433
following pioglitazone were associated with increased adipocyte cell surface and systemic adiponectin 434 levels, supports the centrality of AT to the cardiometabolic derangement underlying the development 435 of T2D and CVD. 436 
Figure 3 Comparison of adipose gene expression in lean (n=12) versus obese (n=29) groups
Individual subject IRS-1 and TNF-α mRNA expression was normalised to the housekeeping gene RPLP0 using the formula ΔCt and the mean fold change relative to the lean control group calculated using the formula 2^-ΔΔCt . Data shown as group mean fold change and statistical analyses were performed on the individual ΔCt values. Differences between lean and obese groups at baseline were analysed using independent t-tests: *p<0.05. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
Lean Obese
Figure 4 Correlations between adipocyte cell surface (μm 2 ) and BMI, % of CD68 expressing cells and % of peripheral CD14 + /CD16 + monocytes (a); correlations between adipocyte cell surface (μm 2 ) and fasting insulin (mU/L) and HOMA index (b); correlation between % of CD68 expressing cells and % of peripheral CD14 + /CD16 + monocytes (c);
Correlations between continuous variables were assessed by Pearson's coefficients for correlations. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
